Privately held Pulmonx (Denver) said data from two recent studies provide evidence that could lead to doubling the amount of emphysema patients treated with its Zephyr Endobronchial Valve (EBV). The company presented at the American Thoracic Society (ATS; New York) Annual Meeting six-month results of the STELVIO trial and the VENT study, which demonstrated a statistically significant benefit in severe emphysema patients with homogeneous disease who received treatment with Zephyr.